Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01695941
Title Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)

B-cell lymphoma

mantle cell lymphoma


Alisertib + Bortezomib + Rituximab

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Montefiore Medical Center-Einstein Campus Bronx New York 10461 United States Details
Montefiore Medical Center - Moses Campus Bronx New York 10467 United States Details
Laura and Isaac Perlmutter Cancer Center at NYU Langone New York New York 10016 United States Details
Fox Chase Cancer Center Philadelphia Pennsylvania 19111 United States Details
*Shaded cells indicate that there was no data available from for the field